Celon PharmaS.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2012-10-25
Share capital
5 385 650,00 PLN
Activity description

Celon Pharma is an integrated pharmaceutical company conducting advanced scientific research and manufacturing modern medicines. The company also markets its own pharmaceutical products.

Registered address
Ogrodowa 2A, 05-092 Kiełpin, Poland
Website
celonpharma.comWebsite active
Email
Email address current
Electronic delivery address
AE:PL-58206-76240-RVIES-16

Financials

The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Stock quotes

PLN 18.70
0.00 (0.00%)
18.5018.6018.7018.8018.9018.7010:0012:0014:0016:00
Open
PLN 18.84
High
PLN 18.88
Low
PLN 18.52
Volume
9.86K
Avg. vol.
16.14K
Market cap
PLN 1.01B
P/E ratio
9.12
EPS
PLN 2.05
Shares outstanding
53.91M
52-week
PLN 18.00 – 20.10
Dividend yield
0.43%
Dividend
PLN 0.08
Ex dividend date
Jun 27, 2024
ISIN
PLCLNPH00015
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 16.23mUSD -2.56mUSD -8.26m
Q1 2026USD 16.71mUSD -1.61mUSD 43.92m
Q4 2025USD 16.16mUSD 634.61kUSD -6.25m
Q3 2025USD 18.60mUSD 2.02mUSD 919.89k

Results for Q3 2026:Nov 18, 2026

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue
This companyUSD 1.53bnMedianUSD 816.16kAverageUSD 29.28m
Net profit
This companyUSD -8.63mMedianUSD 8.96kAverageUSD 2.64m
Operating costs
This companyUSD 57.66mMedianUSD 701.47kAverageUSD 19.26m
Assets
This companyUSD 136.26mMedianUSD 800.13kAverageUSD 29.34m

Industry

Bank accounts

Registered as a VAT taxpayer on 2002-06-25. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

57 public aid cases recorded, with a total value of $144,110,691.

Grant datePurposeGross amountGranting body
Jun 23, 2026
Aid for research and development projects: industrial research
—Prezes Agencji Badań Medycznych
Jun 22, 2026
Aid for research and development projects: industrial research
—Prezes Agencji Badań Medycznych
Jun 22, 2026
Aid for research and development projects: fundamental research
—Prezes Agencji Badań Medycznych

Tenders

No recorded participation in tenders.

Regulatory authorisations

AuthorityTypeStatus
BDO
BDO register entry Active

Authorized Representatives

Krzysztof Dubiel — Attorney-in-fact (joint)
Justyna Rejmak — Management Board Member
Maciej Wieczorek — President of the Management Board
Małgorzata Stokrocka — Management Board Member

Manner of representation

President of the Management Board independently; two members of the management board jointly; one member of the management board jointly with a commercial proxy.

Supervisory board

Artur Wieczorek — Supervisory Board Member
Bogusław Marek Galewski — Supervisory Board Member
Krzysztof Kaczmarczyk — Supervisory Board Member
Robert Rzemiński — Supervisory Board Member
Urszula Wieczorek — Supervisory Board Member

Beneficial owners

PersonRights
Maciej Wieczorek (57)
Glatton sp. zoo

Subsidiaries

NameShare valueStake
Action for Development of Researchsp. z o.o.
342,206.92 USD73.2813%

Competitors

NameRevenueWebsite
Zakłady Farmaceutyczne PolpharmaS.A.$780,704,907.94polpharma.pl
Adamed PharmaS.A.$541,927,181.76adamed.com.pl

Change history

DateEvent
2025-10-10PKD change (Removed: 46.75.Z, 72.11.Z, 72.19; Added: 46.85.B, 72.10.Z)
2024-11-29Share capital change (5,375,650.00 PLN → 5,385,650.00 PLN)
2024-08-06Share capital change (5,105,650.00 PLN → 5,375,650.00 PLN)
2023-08-18Share capital change (5,103,500.00 PLN → 5,105,650.00 PLN)
2022-10-17Share capital change (5,103,000.00 PLN → 5,103,500.00 PLN)

FAQ

Last updated: 2026-09-22